Identification of a Novel Ras-Regulated Proapoptotic Pathway  by Khokhlatchev, Andrei et al.
Current Biology, Vol. 12, 253–265, February 19, 2002, 2002 Elsevier Science Ltd. All rights reserved. PII S0960-9822(02)00683-8
Identification of a Novel Ras-Regulated
Proapoptotic Pathway
Ras polypeptide, thereby creating binding sites for Ras
“effector” proteins [2]. The first Ras effectors to be iden-
tified were the kinases of the Raf subfamily, which are
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and Joseph Avruch1,2,3,5 activated consequent to binding Ras-GTP in vivo and
in turn activate the classic MAPK pathway [3]. It is now1Diabetes Unit and Medical Services
2Department of Molecular Biology well recognized that Ras utilizes effectors in addition to
the Raf kinases. Among the earliest evidence was theMassachusetts General Hospital
3Department of Medicine observation that, although active mutants of both Ras
and Raf can transform cell lines of fibroblastic origin,4Department of Genetics
Harvard Medical School spontaneously occurring active Ras mutants are mostly
found in human tumors of epithelial origin [4]. WhereasBoston, Massachusetts 02114
active Ras alone can transform epithelial cell lines, ac-
tive Raf mutants do not [5]. Certain Ras effector loop
mutants that have lost the ability to bind and activateSummary
Raf and to transform fibroblasts nevertheless can col-
laborate with each other, or with weakly active, non-Background: The Ras-GTPase controls cell fate deci-
transforming Raf mutants, to achieve cellular transfor-sions through the binding of an array of effector mole-
mation [6, 7]. Regarding cellular, wild-type Ras, it iscules, such as Raf and PI 3-kinase, in a GTP-dependent
known that, although at least two peaks of increasedmanner. NORE1, a noncatalytic polypeptide, binds spe-
Ras-GTP charging occur during G1 progression, onlycifically to Ras-GTP and to several other Ras-like
the earlier peak is accompanied by an increase in MAPKGTPases. NORE is homologous to the putative tumor
activity; the relevant effector in mid-late G1 is not knownsuppressor RASSF1 and to the Caenorhabditis elegans
[8]. Direct support for the existence of multiple Ras ef-polypeptide T24F1.3.
fectors comes from the identification of proteins, other
than the Raf kinases, that can bind to Ras in a GTP-Results: We find that all three NORE-related polypep-
dependent manner, including, e.g., the protein kinasestides bind selectively to the proapoptotic protein kinase
MEKK1 and PKC [1]. Whereas the role of these proteinMST1, a member of the Group II GC kinases. Endoge-
kinases in Ras action is unknown, considerable evi-nous NORE and MST1 occur in a constitutive complex
dence indicates that the catalytic subunits of the Typein vivo that associates with endogenous Ras after serum
1 PI 3-kinases are bona fide Ras effectors. These p110stimulation. Targeting recombinant MST1 to the mem-
polypeptides each bind specifically to Ras-GTP throughbrane, either through NORE or myristoylation, augments
a structurally conserved domain; mutation within thisthe apoptotic efficacy of MST1. Overexpression of con-
domain that interrupts Ras-GTP binding increases basalstitutively active Ki-RasG12V promotes apoptosis in a
PI 3-kinase activity and significantly reduces RTK activa-variety of cell lines; Ha-RasG12V is a much less potent
tion of PI 3-kinase activity in vivo [9]. A third class ofproapoptotic agent; however, a Ha-RasG12V effector
probable Ras effectors is the family of guanylnucleotideloop mutant (E37G) that binds NORE, but not Raf or
exchange factors active on the Ral A GTPase (Ral-GDS,PI 3-kinase, exhibits proapoptotic efficacy approaching
Rgl, Rlf). These polypeptides also bind selectively tothat of Ki-RasG12V. The apoptotic action of both Ki-
Ras-GTP through a conserved noncatalytic domain [10].RasG12V and Ha-RasG12V, E37G is suppressed by
In addition, several noncatalytic polypeptides have beenoverexpression of the MST1 carboxy-terminal noncata-
isolated by their ability to bind specifically to Ras-GTP,lytic segment or by the NORE segment that binds MST1.
including AF-6 [11], Rin1 [12], and NORE [13]; the latter
is the subject of this report.Conclusions: MST1 is a phylogenetically conserved
Ras was first identified in mutant, active form as apartner of the NORE/RASSF polypeptide family, and the
retroviral-transforming agent. Moreover, mutations con-NORE-MST1 complex is a novel Ras effector unit that
ferring constitutive Ras activation are found in nearlymediates the apoptotic effect of Ki-RasG12V.
30% of all human tumors [4]. Although active Ras mu-
tants are able to transform nearly all immortalized cell
Background lines, they are usually unable to transform normal pri-
mary cells [14], except in the presence of a cooperating
Ras is a small GTPase imbedded on the inner surface oncogene [15–17] or in association with the loss of cer-
of the plasma membrane whose primary function is to tain tumor suppressor genes [18, 19]. Introduction of
relay proliferative and developmental signals down- constitutively active Ras into primary cells generally re-
stream of cell surface receptors, especially, but not ex- sults in cell cycle arrest mediated by increased levels
clusively, receptor tyrosine kinases [1]. Ras signaling is of a variety of cyclin-dependent kinase inhibitors, or
activated on binding GTP, which results in the reconfigu- in apoptosis [19–21]. Downregulation of the pathways
ration of two epitopes on the cytoplasmic face of the mediating cell cycle arrest and/or apoptosis is probably
crucial to the expression of Ras-induced oncogenesis.
The mechanism by which Ras promotes G1 cell cycle5 Correspondence: avruch@helix.mgh.harvard.edu
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arrest has received considerable attention, whereas the in 90% of small cell lung cancers (SCLC) and in 50%–
mechanism by which constitutively active Ras promotes 80% of non-small cell lung cancers (NSCLC) [28, 29],
apoptosis has been much less extensively explored. breast cancers [30, 31], clear cell renal cancers [32], and
Oncogenic Ras strongly stimulates the activation of p53 several other solid tumors. Moreover, the expression of
through the induction of p14ARF, which neutralizes the the longer isoforms, specifically RASSF1A, is selectively
p53 inhibitor MDM2 [22, 23]. The ability of active alleles extinguished in all SCLC-derived cell lines examined
of Ras to cause apoptosis of primary mouse embryo and in a variety of other tumor-derived cell lines, through
fibroblasts (MEF) is greatly diminished by homozygous mutation, or more frequently, methylation of the RAS-
deletion of the gene encoding p53 [24]. The existence of SF1A promoter [29–32]. Selective reexpression of the
additional p53-independent pathways for Ras-induced RASSF1A polypeptide suppresses the growth in vitro
apoptosis is indicated by the ability of RasG12V to pro- and the tumorgenicity in vivo of these cell lines [29–31].
mote apoptosis if the Ras-induced increase in NFb
activity is suppressed [25, 26] either in p53/ mouse
embryo fibroblasts or in 53/ NIH3T3 cells expressing NORE, RASSF1, and T24F1.3 Each Bind MST1
p53v135, a temperature-sensitive dominant inhibitor of The tumor suppressor function attributed to RASSF1A
p53. Phorbol ester-induced downregulation of PKCs in- together with the presence of an RA domain homolo-
duces apoptosis in Ras-transformed cells [27]. Thus, as gous to that in NORE raised the possibility that these
is true for Ras-induced proliferation, multiple pathways polypeptides might participate in Ras-induced apopto-
exist for Ras induction of apoptosis. In the present re- sis. Surprisingly, in comparison to NORE, neither
port, we identify a novel pathway by which active Ki- RASSF1 nor the C. elegans polypeptide T24F1.3 exhib-
Ras initiates apoptosis through the direct recruitment ited any significant ability to bind directly to RasG12V
of its putative effector NORE, which is stably associated or several related GTPases, as determined quantitatively
with the proapoptotic, Ste20-related protein kinase in a yeast two-hybrid assay, by cotransfection in mam-
MST1. malian cells [33] or by binding in vitro (see below). Thus,
while RASSF1 is unlikely to be a direct mediator of Ras
function, the similarity between NORE, RASSF1A, and
Results the central domain of T24F1.3A suggests that some
evolutionarily conserved function was shared by these
The putative Ras effector NORE is a 413 amino acid proteins. We therefore employed yeast two-hybrid ex-
noncatalytic polypeptide that contains several proline- pression cloning in an effort to identify proteins that
rich motifs between amino acids 17 and 108, a central bound to all three NORE-related polypeptides. In
C1 zinc finger motif (aa 118–165), and a Ras association screening cDNA libraries with either NORE or RASSF1A,
(RA) domain in its carboxy-terminal segment (aa 267– we found several candidates that interacted with both
358) [13]. Although we showed previously [13] that NORE baits; however, only one also bound to T24F1.3, a murine
binds directly to Ras-GTP and is recruited to cRas in vivo cDNA encoding the Ste20-related protein kinase MST1
in response to EGF, the biologic roles and biochemical
(Figure 1A). The prior demonstration that MST1 can act
functions of NORE are as yet unknown
as a proapoptotic agent impelled us to examine further
NORE is most closely related in structure to a family
this evolutionarily conserved interaction. We elected to
of human polypeptides encoded by the RASSF1 gene
focus on the NORE- MST1 interaction, in view of theon Chr3p21 [28, 29]. Five splice variants of RASSF1 have
clear-cut relationship between Ras and NORE.been reported ranging from aa 189 to aa 344. The three
Murine MST1 is a 487 amino acid polypeptide thatlongest RASSF1 isoforms, A, D, and E (340, 344, and
migrates near 60 kDa on SDS PAGE [34, 35]. MST1344 amino acids, respectively), each contain a central
contains an amino-terminal kinase catalytic domain (aaC1 zinc finger upstream of an RA domain and are ap-
30–281; 88% identical to MST2) and a noncatalytic car-proximately 50% identical (75% similar) in amino acid
boxy-terminal tail; its overall architecture and catalyticsequence to the carboxy-terminal 300 amino acids of
domain sequence place it as a Group II GC kinase [36].NORE (Figure 1A). The 270 amino acid RASSF1C isoform
Little is known concerning the physiologic regulation ofis identical over its C-terminal 221 amino acids to the
MST1. As for the targets downstream of MST1, no effectlonger RASSF1 polypeptides but contains a unique 49
on ERK 1/2 activity has been observed, and activationamino acid N-terminal segment; RASSF1C thus lacks
of coexpressed SAPK/JNK or p38 has been observedthe C1 zinc finger motif but contains the RA domain.
in some reports [37], but not others [34, 38]. In contrast,The C. elegans gene product T24F1.3 is a 615 amino
overexpression of MST1 or MST1 (1–330) (but not ki-acid polypeptide containing a unique amino-terminal
nase-inactive MST1) results in apoptosis in several cellsegment, a central C1 zinc finger (aa 165–214), a putative
backgrounds.RA domain (aa 396–495), and a C-terminal extension of
FLAG-tagged versions of NORE, RASSF1A,65 amino acids relative to NORE and RASSF1A; the
RASSF1C, and T24F1.3 each bind specifically with GST-carboxy-terminal 300 amino acids of the latter two poly-
MST1 during transient expression in COS-7 cells (Figurepeptides are each about 40% identical (70% similar) in
1A). The binding site for MST1 is located on the carboxy-amino acid sequence to the central segment of T24F1.3
terminal portions of NORE (Figures 1A and 1B) and RAS-(Figure 1A), suggesting that T24F1.3, which contains the
SF1A (Figure 1A). The site on NORE responsible forC1 and RA domains, is a common precursor to these
binding MST1 was mapped more closely and was showntwo mammalian polypeptides.
to be the carboxy-terminal segment, distal to the RAThe chromosomal segment encompassing the
RASSF1 gene (3p21.3) exhibits loss of heterozygosity domain; thus, fusion of the NORE segment (358–413)
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Figure 1. NORE1 and Its Homologs RASSF1 and T24F1.3 Bind MST1
(A) Binding FLAG-NORE1 homologs by GST-MST1. COS-7 cells were transfected with either a vector (pEBG) endcoding GST or a GST-MST1
fusion protein, together with FLAG-tagged NORE1, NORE (1–267), NORE (251–413), or the NORE1 homologs RASSF1A (full length, 1–340)
RASSF1A (1–119), RASSF1C, or a fragment of the C. elegans polypeptide T24F1.3 (247–601). GST and the various GST fusion proteins were
purified using GSH-agarose and analyzed by immunoblotting after SDS PAGE. Upper panel: proteins retained on GSH beads were probed
with anti-FLAG (M2 monoclonal, Sigma) antibody. Second panel: cell extracts probed with anti-FLAG antibody. Third and fourth panels: cell
extracts probed with anti-GST antibody. Mr, molecular weight markers, kDa. The cartoon indicates the domain features of the NORE-related
polypeptides and identifies the 300 amino acid segment of homology.
(B) MST1 binds NORE carboxy-terminal to the NORE-RA domain. HEK293 cells were transfected with expression vectors encoding GST, GST-
NORE (7–413), or GST-NORE (358–413), the latter at increasing levels as compared with GST-NORE (7–413), together with FLAG-tagged wild-
type MST1, or MST1 Leu444Pro (L444P) or MST1 (L444P), with a frameshift after amino acid 449 that replaces the carboxy-terminal 38 amino
acids of the MST1 with an unrelated 8 amino acid segment (L444PCT). GST and GST fusion proteins were isolated from cell extracts by
adsorption to GSH-agarose and analyzed by immunoblotting after SDS PAGE. Upper panel: proteins retained on GSH beads were probed
with anti-FLAG antibody. Middle panel: cell extracts probed with anti-GST antibody. Lower panel: cell extracts probed with anti-FLAG antibody.
(C) The MST1 carboxy-terminal 32 amino acids are sufficient to bind FLAG-NORE1. COS-7 cells were transfected with expression vectors
encoding GST or GST-MST1 (456–487) together with FLAG-NORE1. GST and GST-MST1 (456–487) were isolated on GSH-agarose and were
analyzed by immunoblotting after SDS PAGE. Upper panel: proteins retained on GSH-agarose beads probed with anti-FLAG antibody. Middle
panel: cell extracts probed with anti-GST antibody. Bottom panel: cell extracts probed with anti-FLAG antibody.
(D) NORE1 binds MST 1, but not related kinases. HEK293 cells were transfected with expression vectors encoding HA-NORE 1 and FLAG-
tagged MST1, GCK, or SOK as indicated. FLAG-tagged proteins were immunoprecipitated with anti-FLAG M2-agarose, eluted with the excess
of the FLAG pepetide. The eluates were analyzed by immunoblotting after SDS PAGE. Upper panel: proteins immunoprecipitated by FLAG-
agarose probed with 12CA5 antibody. Middle panel: cell extracts probed with anti-FLAG antibody. Lower panel: cell extracts probed with
anti-HA antibody.
onto GST is sufficient to confer the binding of full-length The specificity of NORE binding to MST1 was evalu-
ated by the examination of NORE binding to other repre-MST1 (Figure 1B). The MST1 segment responsible for
binding NORE is at the MST1 C terminus. Deletion of sentative GC kinase homologs [36]; thus, GCK or SOK1
do not bind to NORE (Figure 1D). NORE does bind MST2MST1 amino acids 449–487 abolishes binding to GST-
NORE (358–413) (Figure 1B), whereas fusion of the MST1 (data not shown); we have not examined MST3.
C-terminal 33 amino acids (456–487) to GST is sufficient
to enable the specific binding of FLAG-NORE (Figure NORE and MST1 Exist as a Complex In Vivo
We next examined whether endogenous NORE and1C). Moreover, MST1 dimerization is not required for
association to NORE, as the dimerization-deficient MST1 exist in a complex in vivo. As shown previously,
although KB cell extracts exhibit two major bands (atMST1 (L444P) mutant exhibits unimpaired binding to
GST-NORE (358–413) (Figure 1B). 46 kDa and 55 kDa) reactive on immunoblot with our
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Figure 2. A NORE-MST1 Complex Exists In
Vivo
(A) Endogenous NORE1 and MST1 form a
constitutive complex in KB cells. KB cells
were deprived of serum for 24 hr; fetal calf
was added to 10%, and cells were sampled
thereafter at the times indicated. Aliquots of
the cell extracts were incubated with normal
goat IgG or goat anti-MST1 IgG as indicated.
After harvest on protein A/G beads, extensive
washing, and SDS PAGE, the recovered pro-
teins were subjected to immunobloting with
a rabbit polyclonal anti-NORE1 antibody de-
scribed in [13]. Right lane, KB cell extract.
(B) Endogenous MST1 binds recombinant
HA-NORE1 and is displaced by excess re-
combinant MST1. COS-7 cells were trans-
fected with vectors encoding a constant
amount of HA-NORE1 and FLAG vector or
increasing amounts of FLAG-MST1. The HA-
NORE was recovered from cell extracts by
immunoprecipitaion with anti-HA antibody
12CA5 and was subjected to immunobloting
for MST1 and FLAG as indicated. Top panel:
proteins recovered in the HA immunopre-
cipitates probed with anti-MST1 antibody.
Second panel: proteins recovered in the HA
immunoprecipitates probed with anti-FLAG
antibody. Third panel: cell extracts probed
with anti-FLAG antibody; note the increasing
expression of FLAG-MST1. Lowest panel: cell
extracts probed with anti-HA antibody.
polyclonal anti-NORE antibodies (Figure 2A), only the of FLAG-tagged Ha-RasG12V was expressed with a
constant level of FLAG-tagged NORE and increasing46-kDa band was recovered in anti-cRas (Y13-238) im-
munoprecipitates, and only after serum stimulation [13]. amounts of FLAG-tagged MST1. The FLAG-tagged Ha-
RasG12V was precipitated with the anti-Ras antibodyAs shown in Figure 2A, anti-MST1 immunoprecipitates
prepared from KB cells also contain the 46-kDa NORE Y13-238, and the initial cell extracts and the Ras IPs
were probed for FLAG-tagged polypeptides (Figure 3A).polypeptide whose presence is unaffected by serum
deprivation/stimulation (Figure 2A). As seen in the upper panel, the FLAG-MST1 polypeptide
is recovered in the RasG12V immunoprecipitate, butOur polyclonal anti-NORE antibodies do not enable
reliable immunoprecipitation of endogenous NORE. We only in the presence of coexpressed NORE. Moreover,
by comparing the intensities of FLAG-NORE and FLAG-therefore expressed recombinant HA-tagged NORE and
probed the HA immunoprecipitate for endogenous MST1 in the cell extract to that of the Ras IP, it can be
estimated that, in the presence of an excess of RasG12V,MST1; in addition, FLAG-tagged MST1 was expressed
simultaneously in increasing amounts. As seen in Figure about 20% of both FLAG-NORE and coexpressed
FLAG-MST1 are recovered in the RasG12V immunopre-2B, an immunoreactive band is observed in the MST1
immunoblot of the HA-NORE immunoprecipitate that is cipitate. Thus active Ras is able to bind the NORE-MST1
complex. GST-NORE and GST Raf (1–257) each bind inidentical in mobility to the MST1 band observed in the
cell extract. Moreover, the increasing expression of the vitro slightly better to Ki-RasG12V than to Ha-RasG12V,
whereas GST RASSF1A binds neither Ras polypeptideslightly larger FLAG-MST1 is accompanied by the ap-
pearance of increasing amounts of a slightly larger (Figure 3B). We showed previously that the Ras binds
NORE through the Ras effector loop; mutation of RasMST1-reactive polypeptide in the HA-NORE immuno-
precipitates, which ultimately displaces entirely the en- Asp38 to Ala or Asn abolishes Ras binding to NORE
[13]. Here, we examine the ability of several other Ha-dogenous MST1 polypeptide. Thus, MST1 and NORE
form a complex in vivo, which is constitutive (or at least RasG12V effector loop mutants to bind NORE during
transient expression (Figure 3C). The mutation Ha-insensitive to serum withdrawal/addition) and saturable.
RasT35S greatly diminishes, and Y40C abolishes, the
HA-RasG12V-NORE interaction; conversely, the Ha-Active Ras Binds the NORE-MST1 Complex In Vivo
We next determined whether the NORE-MST1 complex RasG12V, E37G mutant exhibits unimpaired (and per-
haps enhanced) binding to NORE.is able to interact with active Ras. A constant amount
MST1 and NORE1 in Ras-Induced Apoptosis
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Figure 3. Active Ras Recruits the NORE-MST1 Complex
(A) RasG12V binds MST1 through NORE1. COS-7 cells were transfected with vectors encoding FLAG-tagged versions of MST1, NORE1, and
HA-RasG12V, using the amounts indicated; each transfection contained 15 g DNA. Aliquots of the cell extracts were mixed with anti-Ras
Y13-238 monoclonal antibody coupled to agarose beads (Santa Cruz). After extensive washing and SDS PAGE, the polypeptides recovered
by Y13-238 (upper panel) and aliquots of the cell extract (lower panel) were subjected to anti-FLAG immunobloting.
(B) Relative binding of HA-RasG12V and Ki-RasG12V to NORE1, RASSF1A, and Raf (1–257) in vitro. HEK293 cells were transfected with pEBG
(encoding GST) or pEBG-NORE (7–413) or pEBG Raf (1–257) or pEBG RASSF1A. Aliquots from extracts of these cells containing comparable
amounts of GST and each of the GST fusion proteins were adsorbed to GSH-agarose. pCMV5 encoding either FLAG Ki-RasG12V or FLAG
Ha-RasG12V were expressed separately in HEK293 cells. Aliquots of extracts from these cells (as shown in the center panel) were adsorbed
to the immobilized GST proteins; the beads were washed extensively and eluted with SDS. The left panel shows an anti-Flag immunoblot,
and the right panel shows an anti-GST blot of this SDS eluate.
(C) Binding of NORE1 to HA-RasG12V with a normal or mutant effector loop. HEK293 cells were transfected with HA-tagged Ha-Ras mutants
G12V (lane 1), G12V T35S (lane 2), G12V E37G (lane 3), or G12V Y40C (lane 4) together with GST-NORE1 (7–413). The latter was isolated from
cell extracts on GSH-agarose, washed, and analyzed by immunoblotting after SDS PAGE. Upper panel: proteins retained on GSH beads were
probed with mouse anti-Ras antibody (AB-2, Calbiochem). Middle panel: cell extracts probed with anti-Ras antibody. Lower panel: cell extracts
probed with anti-GST antibody.
(D) Serum induces the association of endogenous MST1 with endogenous cRas. KB cells were deprived of serum for 24 hr and then stimulated
by the addition of fetal calf serum to 10%; cells were sampled before and at the indicated times after serum readdition. Aliquots of the cell
extracts were mixed with anti-Ras Y13-238 antibody coupled to agarose beads (Santa Cruz). The cell extracts and the washed beads were
subjected to SDS PAGE and analyzed by immunoblotting, as indicated. Upper panel, left four lanes: proteins recovered with Ras Y13-238
immunoblotted with anti-MST1 antibody (Zymed); upper panel, right four lanes: cell extract immunoblotted with anti-MST1 antibody. Lower
panel: Y13-238 immunoprecipitates immunoblotted with mouse anti-Ras antibody (AB-2, Calbiochem).
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The ability of endogenous Ras to bind endogenous membrane enhanced its apoptotic action. To examine
this idea, the amino-terminal myristoylation and polyba-MST1 was evaluated in KB cells. Endogenous cRas was
immunoprecipitated from cell extracts prepared from sic segment of cSrc [40] was fused onto the N terminus
of MST1. Although myristoylation (or coexpression withserum-deprived KB cells and at several times after se-
rum addition; the anti-Ras (Y13-238) IPs were probed excess NORECAAX) tends to decrease MST1 polypep-
tide expression per g of MST1 cDNA in comparisonfor MST1. A band of immunoreactive MST1 is observed
in the cRas IPs only after serum addition and persists to MST1 alone, the apoptotic efficacy (per g DNA) of
myrMST1 was about 2-fold greater than MST1 in NIH3T3for up to 1 hr (Figure 3D); this is similar to the serum-
induced association of endogenous NORE with cRas cells. In addition, side-by-side comparisons in NIH3T3
cells suggest that apoptosis induced by myrMST1 isreported previously [13]. Thus, serum-induced activa-
tion of endogenous Ras causes the recruitment of the about 50% less than by MST1 coexpressed with NORE-
CAAX (Figure 4A). In Jurkat cells, the efficacy ofNORE-MST1 complex to the Ras effector loop.
myrMST1 was only slightly greater than MST1 itself and
much less than that of MST1 coexpressed with NORE-
Membrane Recruitment of MST1 Promotes CAAX (Figure 4B); in contrast, the proapoptotic efficacy
Its Apoptotic Action of myrMST1 in HEK293 cells (Figure 4C) was markedly
We sought next to define the functional significance of greater than MST1, and in three experiments, only
the Ras-NORE-MST1 interaction to the pleiotypic array slightly less than MST1 coexpressed with NORECAAX.
of cellular responses mediated by Ras. The immediate Thus, the apoptotic effect of MST1 is generally in-
downstream targets of MST1 are unknown; however, it creased by membrane targeting, either by myristoyla-
has been consistently observed that overexpression of tion, or most consistently by coexpression with a mem-
recombinant MST1 results in apoptosis in a number brane-targeted variant of NORE.
of cell backgrounds [37–39]. Although the pathway by
which MST1 promotes apoptosis is unknown, we chose
to employ apoptosis as a quantifiable measure of the RasG12V Promotes Apoptosis through
a NORE-MST1 Complexefficacy of MST1 action in vivo.
As expected from previous reports, transient expres- The ability of Ras to recruit a NORE-MST1 complex,
coupled with the increased apoptotic efficacy of mem-sion of MST1 results in apoptosis in several cell types,
measured either as an increase in Annexin V surface brane-targeted MST1, is consistent with the possibility
that the NORE-MST1 complex could act as a proapo-binding (Figure 4A) or as a decrease in the percent sur-
vival of transfected cells (Figures 4B and 4C). An initial ptotic effector of constitutively active forms of Ras. We
tested this idea using HEK293 cells, in view of the high-series of studies was carried out in NIH3T3 cells (Figure
4A); overexpression of MST1 gave a 2-fold increase in grade apoptosis observed with myrMST1 or NORECAAX
plus MST1 in this cell background. Overexpression ofthe fraction of cells staining with Annexin V at 24 hr after
transfection, whereas MST1 (KR) gave no alteration as Ki-RasG12V in 293 cells efficiently induces cell death
(Figure 5A). In contrast, Ha-RasG12V gives no significantcompared to vector control. NORE alone caused a sta-
tistically significant but very small increase in Annexin cell death, in spite of the consistently higher Ha-Ras
polypeptide expression achieved when comparable lev-V staining of NIH3T3 cells, and the combined expression
of NORE and MST1 yielded Annexin V staining slightly els of Ha-Ras and Ki-Ras DNA are transfected. The ex-
pression of Ki-RasG12V per se is sufficient to cause cell(but not significantly) less than that seen with MST1
alone. By contrast, NORECAAX causes a doubling in the death, which becomes maximal at 48–72 hr; however,
the time course of Ki-RasG12V-induced cell death isfraction of Annexin V-positive cells, and coexpression of
MST1 with NORECAAX resulted in an increase in the considerably accelerated by the addition after transfec-
tion of low amounts of proapoptotic agents like tamoxi-fraction of Annexin V-stained cells that was significantly
(about 50%) greater than the sum of the effects of MST1 fen or staurosporine at concentrations below those ca-
pable of directly inducing apoptosis in HEK293 cellsand NORECAAX individually (Figure 4A) and (in two ex-
periments) comparable to the proapoptotic effect of transfected with empty control vectors.
Although commonly considered interchangeable, aBax (data not shown). The ability of NORECAAX and
MST1 to promote Annexin V staining was fully sup- number of differences in the biologic responses to Ha-
RasG12V and Ki-RasG12V have been observed pre-pressed by inclusion of zVAD-FMK in the medium after
transfection (Figure 4D). A similar pattern of responses viously [41]. Of particular note [42], Ha-RasG12V is con-
siderably (7-fold) more effective in activating PI 3-kinaseto NORE and NORECAAX, singly and in combination
with MST1, was seen in Jurkat (Figure 4B) and HEK293 than is Ki-RasG12V. Reasoning that the greater ability
of Ha-RasG12V to activate this major antiapoptotic ef-cells (Figure 4C). In both cells’ backgrounds, MST1 (but
not the inactive MST1 KR mutant) and NORECAAX fector may suppress the expression of a concomitant
proapoptotic outflow, we examined the proapoptoticcaused a dose-dependent (examined in Jurkat only) in-
crease in apoptosis, and the combination of low doses effect of the Ha-Ras effector loop mutant G12V, E37G,
which is unable to bind PI 3-kinase and Raf yet remainsof NORECAAX with MST1 caused additive (Jurkat) or
superadditive (HEK293) killing, which was suppressed competent to bind NORE (Figure 3C); Ha-RasG12V,
E37G elicits substantial cell death in 293 cells, exhibitingby the presence of BV p35 CrmA plus BclXL or incubation
with zVAD-FMK (data not shown). perhaps 2/3 the potency of Ki-RasG12V (Figure 5A).
The cell death elicited by Ki-RasG12V and Ha-RasG12V,The ability of NORECAAX to augment the response
to MST1 suggested that the recruitment of MST1 to the E37G is inhibited by coexpression with the baculoviral
MST1 and NORE1 in Ras-Induced Apoptosis
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Figure 4. Membrane Recruitment Amplifies the Proapoptotic Effect of MST1
(A) The effects of NORE and MST1 on Annexin V surface binding in NIH3T3 and Jurkat cells. The number of observations for each condition
is indicated. Where n  3, the SE is shown; where n 	 2, the error bars indicate the range of values. An asterisk indicates that p 
 .001
versus vector; a plus sign indicates that p 
 .01 versus vector; a multiplication sign indicates that p 
 .001 versus MST; a number sign
indicates that p 
 .05 versus MST. The efficiency of NIH3T3 transfection was about 33%, as determined by counting GFP-positive cells
transfected with a GFP reporter. The Jurkat data are from a single experiment; additional Jurkat experiments, analyzed by second method,
are shown in Figure 4B.
(B) The effects of NORE and MST1 on the survival of Jurkat Tag cells. Three series of experiments are shown; the number (n) of individual
experiments is indicated. In the series shown as n 	 5, this number of observations applies only to the transfection of 8 g cDNA for MST1
and NORECAAX; the cell survival values indicated for MST1, 12–20 g, and NORECAAX, 10 and 15 g, represent the average of two
experiments, and no error bars are shown for these values. The comparison of MST1 (K59R) to vector was done twice; the error bar represents
the range of values observed. Otherwise, SE are shown. An asterisk indicates that p 
 0.001 versus vector; a plus sign indicates that p 

0.01 versus vector; a multiplication sign indicates that p 
 0.05 versus vector.
(C) The effects of NORE and MST1 on cell death in HEK293 cells. A set of three experiments is summarized. The SE is shown. An asterisk
indicates that p 
 0.001 versus vector; a multiplication sign indicates that p 
 0.05 versus vector.
(D) The caspase inhibitor zVAD-FMK suppresses NORE1 and MST1-induced Annexin V binding. NIH3T3 cells were transfected in duplicate
with vectors encoding either NORECAAX together with wild-type MST1, or with myrMST1. zVAD-FMK (42 M) was added at the time of
transfection, as indicated. The cells were harvested 24 hr later, stained with Annexin V-Alexa 488, and analyzed by FACS as described in the
Experimental Procedures.
antiapoptotic protein p35 CrmA (Figure 5B and data not tecture, and nuclear and cytoplasmic fragmentation re-
sulting in apoptotic bodies (Figure 5C). In addition, coex-shown) or by preincubation with zVAD-FMK (data not
shown). Moreover, although the appearance of HEK293 pression of Ki-RasG12V with dominant inhibitory mutants
of caspase 3, 6, 7, and 9 each substantially suppressedcells overexpressing Ha-RasG12V did not differ signifi-
cantly from GFP controls, expression of Ki-RasG12V the Ki-RasG12V-induced cell death, whereas dominant
inhibitory caspase 8 had no effect (Figure 5B). Thus,and Ha-RasG12V, E37G is accompanied by changes in
cell morphology characteristic of apoptotic cell death, the cell death elicited by Ki-RasG12V and Ha-RasG12V,
E37G in HEK293 cells reflects a caspase-mediated pro-i.e., prominent membrane blebbing, loss of cytoarchi-
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Figure 5. Ki-RasG12V and Ha-RasG12V, E37G Induce Apoptosis through a NORE-MST1 Complex
(A) Ki-RasG12V and Ha-RasG12V, E37G induce death in HEK293 cells, which is suppressed by interfering fragments of NORE and MST. The
number of observations for each condition is indicated on the right. The SE is shown, except for n 	 2, where error bars indicate the range
of values. An asterisk indicates that p 
 0.001 versus vector; a plus sign indicates that p 
 0.0001 versus Ki-RasG12V; a multiplication sign
indicates that p 
0.001 versus Ha-RasG12V, E37G.
(B) The effect of various caspase inhibitors on Ki-RasG12V induced death in HEK293 cells. Cells were transfected with empty vectors or
vectors encoding Ki-RasG12V alone, or together with vectors encoding p35 CrmA catalytic inactive mutants of individual caspases: Caspase3
(DNC3), Caspase 6 (DNC6), Caspase7 (DNC7), Caspase 8 (DNC8), or Caspase 9 (DNC9). The error bars represent the SD of replicate
determinations in a single experiment.
(C) The effect of RasG12V variants on the morphology of HEK293 cells. Subconfluent cultures were cotransfected with plasmids encoding
enhanced GFP together with empty FLAG-pCMV5 or pCMV5 encoding Ha-RasG12V or Ki-RasG12V or Ha-RasG12V, E37G. The cells were
maintained in the absence of tamoxifen or other proapoptotic agents and photographed 24 hr after transfection.
(D) Constitutively active variants of the PI 3-kinase catalytic subunit suppress Ki-RasG12V-induced apoptosis. The values shown are the mean
and standard deviation of triplicate measurements from a single experiment. A second experiment gave similar results.
cess probably occurring primarily through activation of boxy-terminal noncatalytic segment of MST1 (intro-
duced as FLAG-MST1 [307–487]) were each able to in-the “intrinsic” (i.e., TNF receptor superfamily- and cas-
pase 8-independent) pathway. The apoptosis induced terfere specifically with apoptosis induced by Ki-
RasG12V and Ha-RasG12V, E37G (Figure 5A). Neitherby Ki-RasG12V is potently suppressed by coexpression
with constitutively active variants of the PI 3-kinase p110 GST-NORE (358–413) nor FLAG-MST1 (307–487) ex-
pressed alone altered cell survival; conversely, expres-catalytic subunit (Figure 5D).
We sought next to determine whether the ability of sion of either fragment inhibited nearly completely the
ability of Ki-RasG12V and Ha-RasG12V, E37G to induceKi-RasG12V and RasG12V, E37G to bind the NORE-
MST1 complex was critical to their proapoptotic action. apoptosis. The inhibitory action of the NORE and MST1
carboxy termini was specific for apoptosis initiated byThis was evaluated by examining whether overexpres-
sion of the segment of NORE responsible for binding RasG12V; neither the GST-NORE fusion nor the MST1
carboxy-terminal segment inhibited Fas-induced apo-MST1 (introduced as GST-NORE [358–413]) or the car-
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ptosis in the Jurkat cell background (data not shown). related proteins and found that only the protein kinase
MST1 exhibits such binding. Reciprocally, an extensiveThus, sequestration of MST1 (by GST-NORE [358–413])
or expression of the MST1 noncatalytic segment, which two-hybrid screen of a human lung cDNA library using
MST1 as bait resulted in the recovery of all five of thecontains autoinhibitory, dimerization, and NORE binding
domains, each inhibits selectively the ability of Ki- known members of the NORE/RASSF gene family (i.e.,
NORE1, RASSF1,2,3, and Ado37), which, in aggregate,RasG12V and Ha-RasG12V, E37G to promote apoptosis.
accounted for 30% of all MST1-interacting proteins re-
covered (Nedwidek et al., unpublished data). Thus,MST1 Kinase Activity
MST1 is a phylogenetically conserved partner of allWe next inquired whether NORE and/or RasG12V regu-
NORE-related peptides. The function of T24F1.3 is un-late MST1 kinase activity. The readditon of serum to 293
known, and although RASSF1A is a candidate tumoror KB cells deprived overnight did not alter the activity of
suppressor [28, 29], its biochemical functions and theimmunoprecipitated endogenous MST1. Cotransfection
regulatory elements upstream of RASSF1A are also un-of MST1 (and in one experiment, MST2) with an excess
known. The ability of MST1 to engage in a ternary com-of NORE was accompanied by an increase in MST1
plex with Ras-GTP and NORE was consistent with theexpression; however, the specific activity of MST1 as-
possibility that MST1 could act as a physiologic effectorsayed in vitro was suppressed by up to 80% (see the
of Ras. We therefore chose to evaluate first the role ofSupplementary Material available with this article on-
NORE-MST1 in Ras action.line). Serum readdition in the presence of coexpressed
Little is known concerning the substrates or immedi-NORE did not cause significant alteration in the activity
ate downstream targets of MST1/2; however, severalof recombinant MST1 or in its mobility on SDS PAGE.
reports have shown that overexpression of MST1 willThe coexpression of Ha- or Ki-RasG12V with MST1, or
promote apoptosis in a variety of cells [37–39]. We there-with a NORE-MST1 complex, gave no consistent change
fore utilized apoptosis as an indicator of the action ofof MST1 activity (see the Supplementary Material). The
recombinant MST1 in vivo. In the three cell backgroundsapparent suppression of recombinant MST1 activity by
examined in this study (NIH3T3, Jurkat, and HEK293)coexpression with NORE and the absence of RasG12V-
using different assays (Annexin V externalization; zVAD-induced alteration in the activity of recombinant MST1,
FMK/BV p35-suppressible increase in cell permeabilityas well as the observation that serum induces the bind-
or nuclear fragmentation), we confirmed that MST1ing of an endogenous NORE-MST1 complex to endoge-
causes a dose-dependent increase in apoptosis andnous Ras without detectably altering the catalytic activ-
found that fusion of the membrane-targeting amino-ter-ity of MST1 assayed in vitro, taken together suggest
minal myristoylation motif from cSrc onto MST1 in-that Ras controls MST1 signaling primarily by its recruit-
creased its apoptotic efficacy, substantially in NIH3T3ment of MST1 to a site critical for MST1 action.
and HEK293 cells and slightly in Jurkat cells. Moreover,
fusion of the carboxy-terminal membrane-targeting mo-
Discussion tif from Ki-Ras4B onto the NORE carboxy terminus, to
give NORECAAX, conferred on NORE the ability to in-
NORE is a noncatalytic protein that binds Ras and sev- duce apoptosis consistently in all three cell back-
eral other GTPases in the Ras subfamily in a GTP-depen- grounds. Moreover, coexpression of NORECAAX with
dent manner in vitro and in vivo [13, 33]. The ability of MST1 (in NIH3T3 and HEK293 cells) yielded cell death
serum and EGF to stimulate the association of NORE in excess of the sum of both agents individually and
with both endogenous and recombinant Ras in several equal or greater than that seen with myrMST1.
cell backgrounds supports the view that NORE is among Seeking a model to test the role of endogenous NORE-
Ras’ physiologic effectors. Seeking evidence of NORE MST1 in the proapoptotic actions of Ras, we examined
function, we were intrigued by the considerable (50%) the ability of transiently overexpressed RasG12V to pro-
identity in amino acid sequence between the carboxy- mote apoptosis. We found that transiently overex-
terminal 300 amino acids of NORE and the putative pressed Ha-RasG12V gave little or no apoptosis in sev-
tumor suppressor protein RASSF1A, one of the longer eral cell backgrounds. Review of the literature indicated
(340 aa) splice variants of the RASSF1 gene. Moreover, that Ha-RasG12V-induced apoptosis has been consis-
the 300 amino acid homologous segments of NORE tently observed only under circumstances of massive
and RASSF1A are each 40% identical in amino acid overexpression, e.g., Ha-RasG12V driven by an IPTG-
sequence to a segment of the protein product of the C. inducible promoter in Rat1 or NIH3T3 cells [43] or by
elegans gene T24F1.3 (Figure 1A). We reasoned that this direct microinjection of plasmid-encoding Ha-RasG12V
strong conservation in primary sequence indicated that [26]. In contrast, overexpression of Ki-RasG12V in
one or more functions mediated by this segment were HEK293 cells gave robust apoptosis; substantial apo-
also strongly conserved. In as much as all three seg- ptosis was also induced by Ki-RasG12V in Jurkat cells
ments contain a Ras/Rap association (RA) domain, we (data not shown). Whereas differential effects of Ki-
considered it probable that this conserved function was RasG12V and Ha-RasG12V on apoptosis have not been
binding to an active Ras-like GTPase. We were surprised noted previously, differential effects of these two Ras
however to discover that neither RASSF1 nor T24F1.3 homologs on other downstream responses are known
exhibited any significant association with Ras or several [41, 43, 44]. The much weaker proapoptotic effect of
Ras-like GTPases ([33] and Figure 3B). We next surveyed Ha-RasG12V as compared with Ki-RasG12V could be
an array of NORE/RASSF1 interactors isolated by two- due to weaker activation of a proapoptotic effector or
to a stronger activation of an antiapoptotic outflow (orhybrid screens for their ability to bind all three NORE-
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both). The finding that Ha-RasG12V, E37G, an effector
loop mutant that is unable to bind Raf or PI 3-kinase,
elicits substantially greater apoptosis than Ha-RasG12V
strongly supports the latter formulation. It is important
to emphasize that, although the proapoptotic effect of
Ki-RasG12V (and Ha-RasG12V, E37G; data not shown) is
suppressed by coexpression with an active PI 3-kinase,
Ras-induced apoptosis is not caused by poor or absent
activation of an antiapoptotic output alone; rather, the
proapoptotic effects of Ki-RasG12V and Ha-RasG12V,
E37G are due to their ability to activate a proapoptotic
stimulus that is not effectively counteracted by a con-
comitant antiapoptotic outflow. The interference experi-
ments indicate strongly that the proapoptotic stimulus
supplied by both Ki-RasG12V and Ha-RasG12V, E37G
requires the participation of NORE and MST1. Thus, Figure 6. A Hypothesis for the Role of MST1 as an Effector of NORE
overexpression of the C-terminal segment of NORE that and RASSF1
binds MST1 in vivo is sufficient to suppress almost com-
pletely the proapoptotic action of Ki-RasG12V and Ha-
RasG12V, E37G. Similarly, overexpression of the C-ter- exhibit significant direct binding to Ras-GTP (Figure 3B)
minal noncatalytic segment of MST1, which contains the or to other Ras-like GTPases, we find that the RASSF1A
MST1 autoinhibitory, dimerization, and NORE binding isoform is able to heterodimerize with NORE and thereby
domains, also strongly suppresses the proapoptotic ac- bind to Ras-GTP indirectly [33]. Thus, recruitment of a
tion of Ki-RasG12V and Ha-RasG12V, E37G. Thus, con- RASSF1A-MST1 complex by an as yet unknown up-
siderable evidence supports the conclusion that the stream regulator (?Ras) may enable the initiation of
ability of Ki-RasG12V and Ha-RasG12V, E37G to induce MST’s apoptotic program (Figure 6).
apoptosis is mediated by the endogenous NORE-MST1 Whatever the role of NORE-MST1 in response to phys-
complex. iologic activation of Ras, the recruitment of NORE-MST1
Although the present data establish that Ki-RasG12V by mutant active Ras is likely to be an important protec-
(and Ha-RasG12V, E37G) induces apoptosis in HEK293 tive mechanism against Ras-induced transformation.
cells through recruitment of the endogenous NORE- The identification of a proapoptotic outflow from Ki-
MST1 complex, we have no evidence as to the functions RasG12V raises the question of whether this property
mediated by the “physiologic” recruitment of NORE- of constitutively active Ki-Ras can be exploited to enable
MST1 engendered by receptor activation of cRas (e.g., the selective apoptosis of cells that have continuous
as in Figure 3D). A few reports have described a require- high-grade Ras activation.
ment for Ras activation in specific apoptotic scenarios,
e.g., as in the TCR-induced expression of FasL [45] or Experimental Procedures
in TNF-induced apoptosis of murine L929 cells [46].
DNA Constructs and ManipulationsAlternatively, apoptosis induced by trophic factor with-
Mouse MST1 cDNA was kindly provided by Dr. Leonard Zon (Chil-drawal in some settings is accompanied by Ras activa-
dren’s Hospital, Boston, MA). cDNAs for human GCK and SOK pro-tion and is inhibited by overexpression of Ras S17N
tein kinases were kindly provided by Dr. John Kyriakis (Massachu-
[47, 48]. Whether cRas-GTP recruitment of NORE-MST1 setts General Hospital, Boston). cDNAs for human V12 Ha-Ras
participates in such proapoptotic phenomena is yet to effector loop mutants E37G, T25S, and Y40C were kindly provided
by Dr. Michael White (Southwestern Medical Center, Dallas, TX).be determined. Alternatively, the “physiologic” recruit-
RASSF1A and RASSF1C cDNAs were kindly provided by Dr. Gerdment of NORE-MST1 by cRas-GTP may initiate down-
Pfeifer (Beckman Research Institute, City of Hope, CA). cDNAs en-stream responses entirely unrelated to the initiation of
coding catalytically inactive caspase 3, 6, 7, 8, and 9 were providedapoptosis, and perhaps only the continuous and/or in-
by Dr. Dale Bredesen and constructed as described by Lu et al.
appropriately intense signaling engendered by Ki- [50]. The baculoviral p35 caspase inhibitor CrmA, encoded in
RasG12V in specific cell backgrounds results in apopto- pCS2, was provided by Dr. Vincent Cryns. C. elegans cDNA encod-
sis (Figure 6). ing amino acids 247–601 of the T24F1.3 gene product was kindly
provided by Dr. Y. Kohara (Japan). The Myc-tagged, constitutivelyIn contrast to the lack of information as to the physio-
active PI 3-kinase p110* was described previously [51]. Humanlogic role(s) of NORE-MST1, several observations sug-
MST2 cDNA was obtained by PCR on a placental library cDNA, withgest that the RASSF1-MST1 complex may function
the primers corresponding to the 5 and 3 ends of the full-length
physiologically as a proapoptotic effector. The RAS- cDNA.
SF1A isoform is a candidate tumor suppressor, whose cDNAs manipulations were performed using the standard mole-
loss of function (e.g., in lung cancers) promotes malig- cular biology techniques [51]. Full-length and truncated NORE1,
RASSF1A, RASSF1C, T24F1.3, MST1, and MST2 cDNAs, as wellnant transformation [29]; a biochemical function as a
as Ki-RasG12V, Ha-RasG12V, and its effector loop mutants wereproapoptotic effector is consistent with such a biologic
subcloned into pCMV5 FLAG vector in-frame downstream of therole. Vos et al. [49] have recently reported that RASSF1
FLAG epitope (MDYKDDDDKNSA). For some constructs, the FLAGoverexpression can itself promote apoptosis. Both RAS-
epitope in pCMV5 was replaced with the influenza virus hemaggluti-
SF1A and the shorter RASSF1C splice variant, which nin epitope (HA, MYPYDVPDYA) by excising the FLAG epitope and
apparently lacks tumor-suppressing activity, bind promoter region from pCMV FLAG plasmid with SacI and EcoRI
enzymes and replacing it with the synthetic oligonucleotide codingMST1. Nevertheless, although neither RASSF1A or -C
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for the promoter region followed by the HA epitope in-frame with (GIBCO-BRL) according to the manufacturer’s instructions. A total
of 2.5  105 293 T cells were seeded in each well of 24-well platesthe downstream sequences. The same approach was used for the
creation of the myristoylated MST1 and NORE1; the FLAG tag of 1 day prior to transfection. Each well was transfected with a total
of 0.5 g DNA and 3.5 l Lipofectamine. After 1 day of incubation,the pCMV 5 was replaced with the cSrc myristoylation and polybasic
segment (MGSSKSKPKDPSQRRR), followed by four glycine resi- the proapoptotic agent tamoxifen was added at a final concentration
of 20–25 M to increase the rate of apoptosis. Floating cells weredues and an in-frame FLAG tag. The same approach was used to
construct the myristoylated PI 3-kinase catalytic subunit (myr-p110). collected at 20–24 hr after the addition of tamoxifen, and cell death
was assessed by trypan blue exclusion as before [55, 56].The p110* was digested with BamH1, releasing a 2.8-kb insert en-
coding full-length p110 with a C-terminal Myc epitope. This was
inserted in-frame downstream of the cSrc myristoylation and poly- Supplementary Material
basic segment and FLAG epitope in the pCMV5 vector. The fusion Supplementary Material including data regarding the regulation of
of the carboxy-terminal Ki-Ras4B membrane-association segment endogenous and recombinant MST kinase activity by serum with-
(CAAX, SKDGKKKKKKSKTKCVIMstop) onto the NORE carboxy ter- drawal and readdition and by coexpression with NORE1 and active
minus to create NORECAAX was accomplished by PCR, using a mutants of Ha- and Ki-Ras is available at http://images.cellpress.
wild-type NORE template, replacing the NORE stop codon with the com/supmat/supmatin.htm.
first amino acid(s) of the CAAX segment. The C-terminal pieces of
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